1. Scrip
  2. >>Business

Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing

 
• By Anju Ghangurde

Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.

Glenmark readies launches amid challenging US environment • Source: Shutterstock

Glenmark Pharmaceuticals Limited has had a difficult run in the US in the fiscal first quarter though the firm expects things to steady hereon as new launches kick in, including the anticipated debut of Ryaltris (olopatadine hydrochloride/mometasone furoate nasal spray) “anytime now”.

At the earnings call for the fiscal first quarter ended 30 June 2022, Glenmark’s leadership echoed what some peers have been flagging up over the recent past – business in the US has been rather tough

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.